Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Zoledronate Versus Ibandronate Comparative Evaluation: A Randomized Phase III, Open-Label, Multicenter, Parallel Group Clinical Trial to Evaluate and Compare the Efficacy, Safety Profile and Tolerability of Oral Ibandronate Versus Intravenous Zoledronate in the Treatment of Breast Cancer Patients With Bone Metastases
Brief Summary: RATIONALE: Ibandronate and zoledronate may help relieve some of the symptoms caused by bone metastases. It is not yet know whether ibandronate is more effective than zoledronate in treating bone metastases from breast cancer.

PURPOSE: This randomized phase III trial is studying ibandronate to see how well it works compared with zoledronate in treating patients with newly diagnosed bone metastases from breast cancer.


Options:
A: Arm Label: zoledronic acid; Type: ACTIVE_COMPARATOR; Interventions: Drug: Zoledronic Acid | Arm Label: denosumab; Type: EXPERIMENTAL; Interventions: Biological: Denosumab | Intervention Type: BIOLOGICAL; Name: Denosumab; Assigned to Arm(s): denosumab | Intervention Type: DRUG; Name: Zoledronic Acid; Assigned to Arm(s): zoledronic acid
B: Arm Label: Ibandronic Acid; Type: EXPERIMENTAL; Interventions: Drug: ibandronate sodium | Arm Label: Zoledronic Acid; Type: ACTIVE_COMPARATOR; Interventions: Drug: zoledronic acid, Drug: Zolendronic Acid | Intervention Type: DRUG; Name: ibandronate sodium; Assigned to Arm(s): Ibandronic Acid | Intervention Type: DRUG; Name: zoledronic acid; Assigned to Arm(s): Zoledronic Acid | Intervention Type: DRUG; Name: Zolendronic Acid; Assigned to Arm(s): Zoledronic Acid
C: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: 5-FU, Epirubicin, Cyclophosphamide, Docetaxel | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: 5-FU, Epirubicin, Cyclophosphamide, Docetaxel, Zoledronic acid | Intervention Type: DRUG; Name: 5-FU, Epirubicin, Cyclophosphamide, Docetaxel; Assigned to Arm(s): A | Intervention Type: DRUG; Name: 5-FU, Epirubicin, Cyclophosphamide, Docetaxel, Zoledronic acid; Assigned to Arm(s): B
D: Arm Label: Zometa; Type: EXPERIMENTAL; Interventions: Drug: Zometa, Drug: Epirubicin, Drug: Docetaxel, Drug: Trastuzumab, Radiation: External beam radiation, Procedure: Modified radical mastectomy or breast conserving surgery with axillary lymph node dissection | Arm Label: No Zometa; Type: ACTIVE_COMPARATOR; Interventions: Drug: Epirubicin, Drug: Docetaxel, Drug: Trastuzumab, Radiation: External beam radiation, Procedure: Modified radical mastectomy or breast conserving surgery with axillary lymph node dissection | Intervention Type: DRUG; Name: Zometa; Assigned to Arm(s): Zometa | Intervention Type: DRUG; Name: Epirubicin; Assigned to Arm(s): No Zometa, Zometa | Intervention Type: DRUG; Name: Docetaxel; Assigned to Arm(s): No Zometa, Zometa | Intervention Type: DRUG; Name: Trastuzumab; Assigned to Arm(s): No Zometa, Zometa | Intervention Type: RADIATION; Name: External beam radiation; Assigned to Arm(s): No Zometa, Zometa | Intervention Type: PROCEDURE; Name: Modified radical mastectomy or breast conserving surgery with axillary lymph node dissection; Assigned to Arm(s): No Zometa, Zometa

Answer: B